Pulmatrix licenses novel drug candidates from RespiVert

13 June 2017

US biopharma firm Pulmatrix (Nasdaq: PULM) has entered into an exclusive, worldwide license agreement with RespiVert, a unit of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech.

Through the agreement, financial terms of which were not disclosed, Pulmatrix gains access to a portfolio of novel drug candidates in a class called kinase inhibitors that the company plans to develop. The deal covers both respiratory and oncology uses of the drug candidates, and Pulmatrix will assume all development and commercialization activities worldwide.

"We believe these innovative compounds licensed from RespiVert Ltd will offer a new approach for treating lung inflammation in diseases like chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF)," said Pulmatrix chief executive Robert Clarke, noting that "they are also perfectly suited for formulation with our iSPERSE technology."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK